A study demonstrated that enhancing the SASP in senescent ovarian cancer cells using topoisomerase 1 (TOP1) inhibitors like irinotecan sensitized tumors to anti-PD-1 therapy.218 This approach resulted in elevated infiltration of activated CD8 + T cells and dendritic cells into the tumor bed, leading to reduced tumor burden and improved survival in a syngeneic mouse model. This evidence concerns the gene TOP1 and neoplasm.